Schreckenberg Rolf, Wolf Annemarie, Szabados Tamara, Gömöri Kamilla, Szabó István Adorján, Ágoston Gergely, . . . Schlüter Klaus-Dieter. (2022). Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo.
Chicago Style (17th ed.) CitationSchreckenberg Rolf, et al. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo. 2022.
MLA idézésSchreckenberg Rolf, et al. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo. 2022.
Figyelem: ezek az hivatkozások nem 100%-ban pontosak..